Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

FGEN vs CELU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FGEN Captures Overall Composite Edge (61.2 BUY vs 42.9 HOLD), While CELU Leads 3–2 on Growth & Valuation Pillars

FGEN Overall Winner 6-Pillar Tally: FGEN 2 – 3 CELU (1 Tie) Matrix Metrics: FGEN 9 – 1 CELU

As of Nov 20, 2026, FibroGen, Inc (FGEN) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (61.2/100 BUY vs. 42.9/100 HOLD) after splitting the core matrix 9–1 (led by Valuation Multiples, Growth & Scale), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. FGEN trades at $9.71 (61.4x Forward P/E, -499.1% operating margin) versus CELU at $0.46 (N/M Forward P/E, -254.0% operating margin).

  • Growth vs. Quality Trade-Off: FGEN earns the overall head-to-head edge with a stronger Unified Composite Score (61.2/100 BUY vs. CELU 42.9/100 HOLD) and -20.79β · 102% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: FGEN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 59.2); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FGEN vs CELU
FGEN NASDAQ Head-to-Head Winner
FibroGen, Inc
Pharmaceutical Preparations
$9.71
+7.65% 1D
Market Cap $36.5M
TTM Revenue $8.3M
Forward P/E 61.4x
Beta / 30D Vol -20.79β · 102% Vol
Unified Composite Score
61.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 59.2 · SMA20: $8.88 · SMA50: $9.26
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 2.01β · 135% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.71 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (FGEN 2 – 3 CELU)

Columns: Metric · FGEN · CELU
1. Valuation Multiples FGEN
Forward P/E 61.4x N/M
Trailing P/E 61.4x N/M
PEG Ratio N/M N/M
EV / Revenue 4.4x 2.7x
2. Growth & Scale FGEN
Revenue Growth (YoY) +774.8% -5.3%
Earnings Growth (YoY) +53.6% -61.3%
TTM Revenue (USD) $8.3M $19M
Market Cap $36.5M $15.2M
3. Profitability & Quality CELU
Gross Margin N/A 19.2%
Operating Margin -499.1% -254.0%
Net Profit Margin 2598.9% -245.7%
Return on Equity (ROE) -1015.8% -6367.2%
4. Balance Sheet & Cash Flow CELU
Cash Generation (TTM) -$58M EBITDA -$8.9M
Cash Flow Margin N/A -47.8%
Net Cash / Leverage -1015.8% ROE $35M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CELU
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 116.6% (50th %ile)
Put/Call OI Skew N/A 3.60x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FGEN (9) vs CELU (1)
Institutional Metric FGEN CELU Criterion Row Edge
Market Capitalization
Scale
$36.5M $15.2M Larger Scale FGEN
Trailing P/E Ratio
Valuation
61.4x N/M Lower Multiple FGEN
Forward P/E Ratio
Valuation
61.4x N/M Lower Multiple FGEN
Revenue Growth (YoY)
Growth
+774.8% -5.3% Higher Growth FGEN
Operating Margin (TTM)
Profitability
-499.1% -254.0% Higher Margin CELU
Net Profit Margin
Profitability
2598.9% -245.7% Higher Margin FGEN
Return on Equity (ROE)
Capital Efficiency
-1015.8% -6367.2% Higher ROE FGEN
52-Week Range Position
Momentum
44% ($0–$22) 2% ($0–$3) Stronger Trend FGEN
Beta / 30D Volatility
Risk Regime
-20.79β · 102% Vol 2.01β · 135% Vol Lower Realized Risk FGEN
Unified Institutional Score
Composite Signal
61.2 / 100 (BUY) 42.9 / 100 (HOLD) Higher Composite FGEN
Trailing 12M Revenue (USD)
Operating Scale
$8.3M $19M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 19.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.4x EV/Rev N/M PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$58M EBITDA (-1015.8% ROE) -$8.9M ($35M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FGEN +53.23 pp
FGEN: +16.57% · CELU: -36.66%
3M Horizon FGEN +40.2 pp
FGEN: +13.57% · CELU: -26.63%
6M Horizon FGEN +40.2 pp
FGEN: +13.57% · CELU: -26.63%
1Y Horizon FGEN +40.2 pp
FGEN: +13.57% · CELU: -26.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FGEN vs CELU. Trailing 12-month operating profitability (FGEN -499.1% vs CELU -254.0%) and valuation multiples (FGEN 61.4x vs CELU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

FGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$8.3M
Gross MarginN/A
Op. Margin-499.1%
ROE / Fwd P/E-1015.8% · 61.4x
CELU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$19M
Gross Margin19.2%
Op. Margin-254.0%
ROE / Fwd P/E-6367.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FGEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CELU BREAKDOWN
60d in phase · OBV NEUTRAL
Current IV 116.6%
IV Percentile 50th %ile
Put/Call OI Skew 3.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FGEN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $36.5M market capitalization and -499.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CELU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FGEN vs CELU Key Questions & Quantitative Answers

As of Nov 20, 2026, FibroGen, Inc (FGEN) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (61.2/100 BUY vs. 42.9/100 HOLD) after splitting the core matrix 9–1 (led by Valuation Multiples, Growth & Scale), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. FGEN trades at $9.71 (61.4x Forward P/E, -499.1% operating margin) versus CELU at $0.46 (N/M Forward P/E, -254.0% operating margin). Growth vs. Quality Trade-Off: FGEN earns the overall head-to-head edge with a stronger Unified Composite Score (61.2/100 BUY vs. CELU 42.9/100 HOLD) and -20.79β · 102% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: FGEN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 59.2); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FGEN leads the Growth & Scale pillar: FGEN posts +774.8% YoY revenue growth and +53.6% YoY earnings growth on $8.3M TTM revenue (N/A gross margin, -499.1% operating margin), compared with CELU at -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin). On trailing 12-month operating scale, FGEN generates $8.3M in USD-normalized revenue versus $19M for CELU. In operating R&D and SG&A reinvestment, FGEN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELU.

FGEN screens cheaper on headline valuation multiples. FGEN trades at 61.4x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported EBITDA margin), whereas CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FGEN (-1015.8% ROE) versus CELU (-6367.2% ROE) capital efficiency.

In options market volatility and institutional positioning, FGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.79β · 102% Vol realized risk). By comparison, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.